Scope Biosciences secures follow-on investment
Scope Biosciences B.V. is a deep tech spin-off from Wageningen University & Research that focuses on CRISPR-based diagnostics. The company has secured a follow-on investment from SHIFT Invest and Oost NL. This investment follows the companies first significant commercial traction and strong progress. Including this new capital, together with a previously awarded €2.5 million EIC Transition Grant and earlier investments, Scope Biosciences has now secured a total of €6 million in seed-stage funding.
scopeDx®: Bringing diagnostics out of the lab
ScopeBio’s main mission is a next-genCRISPR-based molecular diagnostics platform -scopeDx®. scopeDx®deliversultra-precise, single-nucleotide detectionin a format that’sportable and field-ready without proprietary hardware or centralized labs. The technology allows diagnostics to be performed closer to the source, meaning in the field, at the point of care, or directly within agricultural operations. In agriculture this means earlier and more effective detection of crop diseases. For health care it contributes to faster and broader access to reliable testing, especially in areas where centralized laboratories are not available.
“We’re grateful for the continued backing of SHIFT and Oost NL, and proud to have secured significant public and private support as we bring our technology closer to market,” said Niek Savelkoul, CEO and founder of Scope Biosciences.“We’re scaling up, building out our platform and getting ready to meet real-world diagnostic challenges head-on.”
Regional innovation with global impact
Scope Biosciences is headquartered on the Wageningen Campus and is embedded in the vibrant innovation ecosystem of the East Netherlands region. Maureen Haverkamp, Investment Manager at Oost NL: “ScopeBio’s technology aligns perfectly with our ambition to foster regional innovation with global relevance. We are proud to support this pioneering company as it enters its next growth phase.”
